Shuttle Pharmaceuticals Holdings (SHPH) EBT (2021 - 2026)

Shuttle Pharmaceuticals Holdings has reported EBT for 6 years, with the latest figure at -$2.2 million in Q1 2026.

• On a quarterly basis, EBT rose 24.65% year-over-year to -$2.2 million in Q1 2026; TTM through Mar 2026 was -$11.2 million, a 27.75% decrease from a year earlier, with the FY2025 full-year figure at -$11.9 million, down 55.54% from the prior year.
• EBT was -$2.2 million for Q1 2026 at Shuttle Pharmaceuticals Holdings, up from -$2.8 million in the prior quarter.
• The five-year high for EBT was -$524017.0 in Q2 2022, with the low at -$3.9 million in Q2 2025.
• Average EBT over 5 years is -$2.0 million, with a median of -$2.0 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2024: EBT sank 492.21% in 2022, then surged 73.34% in 2024.
• Over 5 years, EBT stood at -$2.7 million in 2022, then climbed by 19.01% to -$2.2 million in 2023, then soared by 73.34% to -$587079.0 in 2024, then slumped by 368.86% to -$2.8 million in 2025, then climbed by 19.03% to -$2.2 million in 2026.
• The last three EBT figures came in at -$2.2 million (Q1 2026), -$2.8 million (Q4 2025), and -$2.3 million (Q3 2025), per Business Quant data.